Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GMAB 
Genmab AS (GMAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GMAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $29.69
1 Year Target Price $29.69
| 4 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.16% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.64B USD | Price to earnings Ratio 12.06 | 1Y Target Price 29.69 |
Price to earnings Ratio 12.06 | 1Y Target Price 29.69 | ||
Volume (30-day avg) 9 | Beta 0.82 | 52 Weeks Range 17.23 - 28.56 | Updated Date 06/30/2025 |
52 Weeks Range 17.23 - 28.56 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 35.27% | Operating Margin (TTM) 26.29% |
Management Effectiveness
Return on Assets (TTM) 11.54% | Return on Equity (TTM) 22.8% |
Valuation
Trailing PE 12.06 | Forward PE 11.19 | Enterprise Value 9560661694 | Price to Sales(TTM) 3.91 |
Enterprise Value 9560661694 | Price to Sales(TTM) 3.91 | ||
Enterprise Value to Revenue 3.07 | Enterprise Value to EBITDA 7.07 | Shares Outstanding 616212992 | Shares Floating 62629388 |
Shares Outstanding 616212992 | Shares Floating 62629388 | ||
Percent Insiders 0.01 | Percent Institutions 10.38 |
Analyst Ratings
Rating 3 | Target Price 29.69 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Genmab AS
Company Overview
History and Background
Genmab AS, founded in 1999 in Copenhagen, Denmark, is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer and other diseases. It has evolved from a research-focused entity to a commercial-stage biopharmaceutical company through strategic partnerships and internal innovation.
Core Business Areas
- Research and Development: Focuses on discovering and developing novel antibody-based therapies. This segment drives innovation and future product pipeline growth.
- Commercialization: Involves the marketing and sales of approved antibody products, generating revenue through direct sales and partnerships.
- Partnerships and Licensing: Collaborates with pharmaceutical companies to co-develop and commercialize products, providing a revenue stream through royalties and milestone payments.
Leadership and Structure
Genmab is led by a management team with expertise in biotechnology, pharmaceuticals, and finance. The organizational structure includes departments for R&D, commercial operations, finance, and legal, facilitating efficient drug discovery and development.
Top Products and Market Share
Key Offerings
- Daratumumab (Darzalex): A CD38-directed antibody approved for multiple myeloma treatment. Co-developed and commercialized with Janssen Biotech (Johnson & Johnson). Darzalex has achieved significant market share within multiple myeloma therapies, facing competition from other myeloma treatments. Global sales are estimated in excess of $9 billion annually. Competitors include Amgen's Kyprolis, Bristol Myers Squibb's Revlimid and Pomalyst, and Takeda's Velcade.
- Epcoritamab (Epkinly): A bispecific antibody targeting CD3 and CD20 for lymphoma treatment. Co-developed and commercialized with AbbVie. Recent approval is expected to have steady revenue growth. Competitors include CAR-T cell therapies and other lymphoma treatments.
- Tisotumab vedotin (Tivdak): An antibody-drug conjugate (ADC) targeting tissue factor (TF) for cervical cancer. Co-developed and commercialized with Seagen (now part of Pfizer). Represents a growing market. Competitors include chemotherapy and other targeted therapies for cervical cancer.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. It is driven by innovation in drug discovery and the need for effective treatments for unmet medical needs.
Positioning
Genmab AS is positioned as an innovative biotechnology company specializing in antibody therapeutics. Its competitive advantage lies in its strong antibody technology platform and successful partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The TAM for antibody therapeutics is estimated to be in the hundreds of billions of dollars. Genmab AS is positioned to capture a significant share of this market through its innovative products and strategic collaborations. TAM exceeds $200B.
Upturn SWOT Analysis
Strengths
- Strong antibody technology platform
- Successful partnerships with major pharmaceutical companies (e.g., Janssen, AbbVie)
- Diverse product pipeline
- Established commercial presence (through partnerships)
- History of Innovative antibody therapeutics
Weaknesses
- Reliance on partnerships for commercialization
- High R&D costs
- Dependence on key products like Darzalex
- Vulnerability to clinical trial failures
- Competition from larger pharmaceutical companies
Opportunities
- Expansion of product pipeline through internal R&D
- Further strategic partnerships for co-development and commercialization
- Expansion into new therapeutic areas
- Increased adoption of antibody therapies
- Emerging biomarkers for therapeutic development
Threats
- Competition from biosimilars
- Clinical trial failures
- Regulatory changes
- Economic downturns
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- AMGN
- PFE
Competitive Landscape
Genmab AS benefits from its specialization in antibody therapeutics and successful partnerships. However, it faces competition from larger pharmaceutical companies with greater resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Genmab AS has experienced significant revenue growth in recent years, primarily driven by the success of Darzalex and other antibody products. This growth is evidence of the company's innovative product pipeline and strategic partnerships.
Future Projections: Analysts project continued revenue growth for Genmab AS, driven by the expansion of existing products and the launch of new antibody therapies. EPS is expected to increase as the company leverages its strong product pipeline.
Recent Initiatives: Recent strategic initiatives include expanding partnerships, advancing new product candidates through clinical trials, and investing in innovative antibody technology.
Summary
Genmab AS is a strong biopharmaceutical company specializing in antibody therapeutics, bolstered by its productive partnerships and revenue growth from key products like Darzalex. Its innovative antibody technology platform and robust product pipeline position it for future expansion. Potential challenges include competition, clinical trial risks, and reliance on partnerships, requiring vigilant management and strategic diversification. Genmab's financial health is secured by healthy cash reserves and low debts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated and may vary. Investors should conduct their own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genmab AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2009-06-01 | Co-Founder, President & CEO Dr. Jan G.J. van de Winkel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2638 | Website https://www.genmab.com |
Full time employees 2638 | Website https://www.genmab.com | ||
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.